X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Analysts give X4 Pharmaceuticals an average recommendation of Hold from five analysts (1 sell, 1 hold, 3 buy) with a $8.50 average 12‑month price target.
• In the latest quarter X4 beat estimates (EPS of -$0.22 vs. -$0.36 expected; revenue $2.57M vs. $1.68M) but remains unprofitable with a -225.55% net margin and analysts forecast -0.68 EPS for the year.
• Institutional investors own 72.03% of the stock, with recent stake increases by Vanguard, Jane Street and Bank of America, while shares trade near $4.33 (market cap ≈ $394M; 12‑month range $1.35–$6.63).

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) has been given an average recommendation of "Hold" by the five analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $8.50.

A number of analysts have commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of X4 Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, March 21st. Finally, Guggenheim assumed coverage on shares of X4 Pharmaceuticals in a research note on Monday, March 9th. They set a "buy" rating and a $12.00 price target for the company.

Institutional Trading of X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of XFOR. Bank of America Corp DE increased its stake in X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company's stock valued at $98,000 after purchasing an additional 22,485 shares in the last quarter. Rhumbline Advisers increased its stake in X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company's stock valued at $44,000 after purchasing an additional 9,690 shares in the last quarter. Jane Street Group LLC grew its stake in shares of X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company's stock worth $185,000 after acquiring an additional 51,544 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of X4 Pharmaceuticals by 77.0% in the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company's stock worth $1,404,000 after acquiring an additional 178,593 shares in the last quarter. Finally, Palumbo Wealth Management LLC bought a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth $326,000. Institutional investors own 72.03% of the company's stock.

X4 Pharmaceuticals Stock Performance

Shares of XFOR stock opened at $4.33 on Thursday. The firm has a market capitalization of $393.68 million, a PE ratio of -1.00 and a beta of 0.32. The firm has a fifty day simple moving average of $3.80 and a two-hundred day simple moving average of $3.72. The company has a current ratio of 10.16, a quick ratio of 9.98 and a debt-to-equity ratio of 0.41. X4 Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $6.63.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.14. The business had revenue of $2.57 million during the quarter, compared to analyst estimates of $1.68 million. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. Analysts forecast that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company's lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström's macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.